



This is an electronic reprint of the original article. This reprint may differ from the original in pagination and typographic detail.

Thiel, Daniel; Blume, Fabian; Jäger, Christina; Deska, Jan

Chloroperoxidase-Catalyzed Achmatowicz Rearrangements

Published in: European Journal of Organic Chemistry

DOI: 10.1002/ejoc.201800333

Published: 07/06/2018

Document Version Peer-reviewed accepted author manuscript, also known as Final accepted manuscript or Post-print

Published under the following license: Unspecified

Please cite the original version: Thiel, D., Blume, F., Jäger, C., & Deska, J. (2018). Chloroperoxidase-Catalyzed Achmatowicz Rearrangements. *European Journal of Organic Chemistry*, 20, 2717-2725. https://doi.org/10.1002/ejoc.201800333

This material is protected by copyright and other intellectual property rights, and duplication or sale of all or part of any of the repository collections is not permitted, except that material may be duplicated by you for your research use or educational purposes in electronic or print form. You must obtain permission for any other use. Electronic or print copies may not be offered, whether for sale or otherwise to anyone who is not an authorised user.

Chloroperoxidase-catalyzed Achmatowicz Rearrangements

Daniel Thiel,^[a,‡] Fabian Blume,^[a] Christina Jäger,^[a] and Jan Deska*^[a]

Abstract: Chloroperoxidase from *Caldariomyces fumago* catalyzes the selective oxidation of furfuryl alcohols in an Achmatowicz-type ring expansion. In combination with glucose oxidase as oxygen-activating biocatalyst, a purely enzymatic, aerobic protocol for the synthesis of 6-hydroxypyranone building blocks is obtained. Thanks to an only modest stereochemical bias of the oxygenating heme protein, optically active alcohols of either configuration are converted without a significant mismatch opening up opportunities for enantioselective multienzymatic cascades. Balancing the oxidase-driven aerobic activation, extended enzyme half-lifes and productive conversion of poorly soluble and slowly reacting substrates can be achieved with high yields of the six-membered O-heterocycles.

Introduction

Over the past decades, the Achmatowicz-type ring expansion^[1] – the oxidative conversion of $\alpha\text{-}heterosubstituted$ furfuryl derivatives to six-membered O- or N-heterocyclic building blocks - has become a valuable tool in modern synthetic organic $chemistry.^{\ensuremath{\text{[2-5]}}}$ Both the easy access to suitable heteroaromatic Achmatowicz substrates as well as the broad range of follow-up chemistry offered by the pyranone or piperidinone products make this transformation an attractive instrument in the synthesis of complex natural products and biologically active agents. While the original procedures by Achmatowicz ^[1,6] and Lefebvre ^[7] still relied on the use of stoichiometric oxidants such as bromine or metachloroperbenzoic acid, over the years multiple powerful variations photoactivation metal catalysis, based on e.g. and electrochemistry have been brought forward providing additional selectivities and broader applicability.^[8] In light of milder and environmentally more benign approaches towards the oxidative ring rearrangement of the furfuryl derivatives, recently the use of enzymes as biological catalyst has been brought into the focus (Scheme 1). Here, both the groups of Beifuss,^[9] and of Rutjes and Hollmann [10] have been successful in the development of bioinduced protocols relying on the biocatalytic generation of diffusible oxidizing species from the interaction of an oxidoreductase with a suitable redox mediator. In the first enzyme-driven report, laccases in combination with TEMPObased redox moderators act as catalytic principle in an aerobic ring expansion to give substituted pyranones utilizing air as terminal oxidant. Similarly to the original Br2-based method by

 [a] Dr. D. Thiel, Dipl.-Chem. F. Blume, Christina Jäger, Prof. Dr. J. Deska
 Department of Chemistry and Materials Science, Aalto-yliopisto Kemistintie 1, 02150 Espoo, Finland
 E-mail: jan.deska@aalto.fi
 www.deskalab.com

[‡] Current affiliation: CAT Catalytic Center, RWTH Aachen University, Worringerweg 2, 52074 Aachen, Germany

Supporting information for this article is given via a link at the end of the document.

Achmatowicz, halonium species generated by the catalytic conversion of hydrogen peroxide as terminal oxidant and bromide through a vanadium-dependent haloperoxidase promote the oxidative furan cleavage that ultimately leads to the sixmembered heterocycles and its efficacy has been demonstrated for the synthesis of both pyranones and piperidinones. In addition to these mediated processes, in 2014 our group established a novel protocol exploiting the oxygenating properties of hemedependent peroxidases in order to catalyze Achmatowicz-type reactions in a truly biocatalytic manner exploiting a direct proteinfuran interaction.^[11] In combination with an oxidase and a cheap sacrificial reductant such as sugars or alcohols for the controlled situ generation of hydrogen peroxide, the aerobic in rearrangement of furfuryl alcohols is achieved.^[12]



Scheme 1. Biocatalytic approaches for the oxidative ring expansion of furfuryl alcohols.

In this paper, we disclose the results of an in-depth study on the initial development and the improvement of an enzyme-catalyzed Achmatowicz protocol based on chloroperoxidase from *Caldariomyces fumago*, including stereochemical investigations on the enantioselectivity of the heme protein and an extended substrate scope analysis. Additionally, a mediated protocol exploiting biocatalytically generated peracetic acid is presented as alternative to overcome the current structural limitations of the wild-type chloroperoxidase.

Results and Discussion

Methodological Studies

Our study towards an enzyme-catalyzed version of the well established Achmatowicz rearrangement commenced with the identification of biological systems that would resemble the key step in the transformation, that is, the oxygenative cleavage of furans to form ketoenal intermediates (Scheme 1).^[13] Here, investigations on the in vivo degradation of furans by cytochrome monooxygenases indicated that heme-dependent P450 oxygenation biocatalysts might provide the required reactivity to be utilized in the title reaction.^[14,15] As relatively cheap commercial alternative to the P450s, we envisaged that heme peroxidases could potentially serve this purpose, and initial studies aimed to elucidate the oxygenating abilities of a set of peroxidases with regard to the conversion of 1-furylethanol (1a). Owing to structural differences in the active site, particularly the nature of the axial heme ligand, only a few peroxidases actually behave in a cytochrome P450-like manner and hence,^[16,17] it was no surprise that classical peroxidases such as soybean-, horseradish- or lactoperoxidase, fueled by a glucose/glucose oxidase H2O2 production system,^[18] did not exhibit major activity in the oxidation of 1a and only in the case of horseradish peroxidase, traces of the desired pyranone 2a were detected after 24 h (Scheme 2). On the other hand, employing the same oxidase-based H₂O₂ delivery tool but changing the peroxidase to a chloroperoxidase from Caldariomyces fumago (CPO) that acts as peroxidase-P450 functional hybrid,[19,20] almost full conversion was observed already after 3 h with a significant amount of 2a (51%) being



Scheme 2. Peroxidase and oxidase screening

formed. Considering the structural similarities between the sugar substrate of the glucose oxidase and the Achmatowicz pyranones, it was first assumed that oxidase activity on the initially formed lactol 2a might attribute to the discrepancy of conversion and yields under the non-optimized reaction conditions. However, spectroscopic analysis of the crude reaction mixtures did not show any traces of the 2a-derived lactone as side product. Also, a photospectrometric oxidase assay coincubating 2a and glucose oxidase (with horseradish peroxidase and ABTS as reporter) remained silent, thus ruling out any undesired cross-reactivity between the sugar oxidase and the sugar-like hydroxypyranone products. Nevertheless, also other oxidase/reductant systems were tested and while both leucine/amino acid oxidase and methanol/alcohol oxidase did not match the outcome of the glucose oxidase-driven protocol, modification of oxidase loading or the reaction environment might give rise to productive Achmatowicz systems in those cases as well.

Yet, considering the generally low cost of both glucose and the glucose oxidase (GOx), subsequent optimization studies were pursued on this most successful initial screening hit. Variation of the pH of the reaction medium (aqueous citrate or phosphate buffers) revealed a rather wide plateau between 4.5 and 6.5 with greater 90% conversion of 1a with 2 h, and a sharp loss of oxygenating power at neutral pH (Figure 1a, left). In the context of pH optimization, it is important to pay attention not only to the enzyme activity but also to the stability of the reaction substrates, in particular with regard to their stereochemical integrity. Therefore, enantiomerically pure (R)-1a was also incubated in absence of any biocatalyst for 24 h after which the optical activity of the recovered starting material was determined. Clearly, due to the benzylic situation of the alcohol, racemization can become an issue at pH values less than 5.5 where slow epimerization is taking place (Figure 1a, right). Consequently, the optimal operation window for the CPO-mediated ring expansion of furfuryl alcohols can be set to pH 5.5 - 6.5.

Next, the influence of cosolvents was addressed in order to additives identifv suitable solubilizing enabling hiah concentrations of the more or less lipophilic furfuryl substrates (Figure 1b). To our delight, addition of 10% tert-butanol to the reaction medium did not affect the enzymes' activity and full conversion of 1a was achieved after 3 h. Yet, in contrast to the purely aqueous medium, pyranone 2a was isolated in greatly improved 82% yield after reaction in the buffer/tBuOH mixture, an effect that could be later attributed to the improved stability of Achmatowicz-type pyranones in the medium (pure buffer: t_{1/2} (2a) = 11.9 h; buffer/tBuOH: $t_{1/2}$ (2a) = 40.7 h). In this medium, the reaction could also be significantly scaled to a total of 50 mmol of 1a at increased concentration (50 mM) and reduced CPO loading (200 U/mmol) with a yield of 76%. Acetone as cosolvent exhibited a similar effect although the activity was slightly reduced, reaching conversion levels >90% only after 6 h. Addition of DMSO or acetonitrile on the other hand resulted in modest inhibition of the reaction and in biphasic reaction media such as buffer/heptane mixtures, no reaction was observed.



a pH influence on enzyme activity & stereochemical integrity

b cosolvent influence on enzyme activity & product selectivity



Figure 1. Optimization of reaction parameters for the CPO-mediated oxidative ring expansion of 1-(2-furyl)ethanol (1a).

Stereochemical Investigations

With an effective biocatalytic Achmatowicz system in hand, next the stereoselectivity of the chloroperoxidase towards different kinds of furans was studied. Starting from racemic 1-(2furyl)alkanols with varying chain length, branching, and functionalization patterns, the extent of enantiodiscrimination in kinetic resolutions of the furans was recorded at low conversion rates (Table 1). In all cases, the tested furan were transformed to the corresponding ring expanded heterocycles and a certain enantioenrichment of the remaining alcohols was observed. Yet the enantioselectivity $E(k_{(R)} vs k_{(S)})$ proved to be mediocre at best. Moreover, there was no obvious trend with regard to steric bias of the side chain as both the slim methyl-substituted furfuryl alcohol 1a as well as the bulky tert-butyl derivative 1h exhibited E values of less than 3 (Table 1, entry 1 & 8). The most effective kinetic resolution took place with the homoallylic alcohol 1e but with relative rates of approximately 10:1 favoring the conversion of the (R)-enantiomer (Table 1, entry 5), synthetically useful optical purities remain elusive. Hence, the production of enantioenriched pyranones by enzymatic resolution must be considered unpractical unless further optimization of the biocatalyst by directed evolution could deliver more specific chloroperoxidase variants.

 Table 1. Enantiodiscrimination in the oxidative conversion of racemic furfuryl alcohols.

rac-1	R glucose oxidase (<i>C. t</i> glucose oxidase (<i>A.</i> D-glucose, tBuOH (10 citrate buffer (pH 5 30 °C, 10 min	fumago) niger) 	Р ОН НС 1	(R)-2
Entry ^[a]	R	conversion [%] ^[b]	ee (1) [%] ^[b]	$\frac{E}{[k_{(R)}/k_{(S)}]^{[c]}}$
1	methyl (1a)	16	6	2.3
2	ethyl (1b)	16	9	3.0
3	<i>n</i> -propyl (1c)	13	9	4.4
4	vinyl (1d)	11	9	6.9
5	allyl (1e)	12	11	10.4
6	<i>i</i> -propyl (1f)	18	11	3.3
7	<i>i</i> -butyl (1g)	12	10	7.2
8	<i>t-</i> butyl (1h)	8	4	2.8
9	phenyl (1i)	12	8	4.2
10	CH ₂ CO ₂ Et (1j)	17	4	1.5

[a] Reaction conditions: alcohol **1** (25 μ mol), D-glucose (125 μ mol), chloroperoxidase (25 U), glucose oxidase (25 U), citrate buffer (2.25 mL, 0.1 M, pH 5.5), *f*BuOH (0.25 mL), 30 °C. Yields determined after purification by column chromatography. [b] Conversions and optical purities determined by chiral gas chromatography using bromobenzene as internal standard. [c] Enantioselectivities calculated according to Sih et al.^[21]

Substrate Scope and Limitations

On the other hand, the lack of substantial enantiodiscrimination by the chloroperoxidase can also be seen as a positive feature of the biocatalytic method since limitations to certain stereoisomers due to matched/mismatched situations become less likely. Considering the general disadvantage of kinetic resolution approaches to be yield-limited to a maximum of 50% of optically pure material, alternative pathways to address enantioenriched pyranone products by combining the stereoselective synthesis of furfuryl alcohols with the subsequent aerobic rearrangement appear highly attractive. In particular, the ketoreductase-mediated alcohol synthesis by reduction of the

FULL PAPER

corresponding furyl ketones opens up great opportunities for an effective, fully enzymatic route to these synthetically valuable building blocks. Based on a previously reported method utilizing two commercial alcohol dehydrogenases (ADH200 & ADH 030 from evoCatal) as asymmetric reduction catalyst,^[11] a set of optically active furylcarbinols was prepared and tested under the optimized conditions for the Achmatowicz-type ring expansion (Table 2). Gratifyingly, both antipodes of the model substrate 1a were converted smoothly and the enantiomeric pyranones (R)-2a and (S)-2a were not only isolated in high yields but also with complete conservation of the stereogenic information (Table 2, entry 1 & 2). Also the homologues (R)-2b and (R)-2c could be obtained in reasonable yields (Table 2, entry 3 & 4), and notably, further improvement of optical purity was observed starting from just moderately enantioenriched 1c (from 95% ee to 98% ee of 2c). Moreover, the CPO-mediated procedure exhibited a high functional group tolerance, not only accepting ester- or chlorosubstituted furylcarbinols (Table 2, entry 6 & 7) but more importantly, providing selectivity in the furan oxidation in presence of oxidation-labile moieties such as olefins and primary

Table 2. Oxidative ring expansion of optically active furfuryl alcohols.

R	R' chlorop glucc OH D-gluca citr: (R)-1	peroxidase (C. fumago ose oxidase (A. niger) ose, fBuOH (10% v/v ate buffer (pH 5.5) 30 °C, 2 h) → HO √ R (/	0 0 R)-2
Entry ^[a]	R/R'	ee (1) [%] ^[b]	yield (2) [%]	ee (2) [%] ^[c]
1	H / methyl (1a)	99	83	99
2	H / methyl (ent-1a)	99	81	99
3	H / ethyl (1b)	99	77	99
4	H / <i>n</i> -propyl (1c)	95	53	98
5	H / allyl (1e)	95	65	98
6	H / CH ₂ CO ₂ Et (1j)	99	64	99
7	H / CH ₂ Cl (1k)	99	68	99
8	H / CH ₂ OH (11)	99	31	99
9	H / ethynyl (1m)	99	0	-
10	methyl / methyl (1n)	99	0	-

[a] Reaction conditions: alcohol 1 (0.5 mmol), D-glucose (2.5 mmol), chloroperoxidase (0.5 kU), glucose oxidase (0.5 kU), citrate buffer (45 mL, 0.1 M, pH 5.5), *t*BuOH (5 mL), 30 °C. Yields determined after purification by column chromatography. [b] Optical purities determined by chiral gas chromatography.

alcohols (Table 2, entry 5 & 8). The propargylic alcohol 1m, however, could not be transformed to the corresponding pyranone. Subsequent coincubation studies with 1a revealed that 1m, and other alkyne additives, exhibit inhibitory properties on the CPO-catalyzed reaction. The core-substituted alcohol 1n on the other hand did not affect the conversion of other substrates in a negative way, yet, also here the CPO/GOx system failed to provide the 2,6-dimethylpyranone 2n.

Despite the mostly convincing yields, optical purities and the good functional group tolerance of the CPO-catalyzed Achmatowicz protocol, the stereochemical investigations and substrate scope studies also revealed some issues related to conversion rates of highly lipophilic long-chain or branched aliphatic furylalkanols in particular. Hereby, the decline in reaction rates, and consequently in product yields, follows a very clear trend along the homologous series from the rapidly reacting furylethanol (1a) to the virtually non-reactive furylheptanol (1q) (Scheme 3). Likewise, incorporation of branched aliphatics results in severely diminished pyranone yields ranging from mediocre 34% for the isopropyl derivative (2f) to only trace amounts of the butyl derivatives 2g and 2h. While unfavorable sterics might be a reason for this effect, the observation that the similarly bulky ester-functionalized substrate 1j performed well in the CPOmediated ring expansion points towards a different explanation where the poor solubility of substrates such as 1g or 1q in the aqueous medium could account for their sluggish conversion. Unfortunately, increased concentrations of tBuOH, that would improve the solubility of lipophilic substrates in the reaction mixture, in turn resulted in rapid enzyme inhibition. Thus, further - studies targeting suitable solubilizing additives seem to be necessary as one option to widen the scope of the reaction to long-chain furylcarbinols.

FULL PAPER



proceeds slowly and after 24 h, 84 % conversion is reached. A subtle balancing of the oxygen-activating and the oxygen-transfer biocatalyst should thus allow for productive enzymatic Achmatowicz rearrangements even of slowly reacting furfuryl substrates.



Scheme 4. Balancing of oxidase and peroxidase activity.

In addition to solubility issues, with a low rate of conversion of the sterically more biased, challenging furfuryl alcohol substrates by the chloroperoxidase, apparently the accumulation of hydrogen peroxide produced by the glucose oxidase at constant rates might become an issue as bleaching of the heme protein at high concentrations of H₂O₂ could account for an enzyme inhibition and the low overall turnover to the desired pyranones.^[22,23] In order to investigate this hypothesis, furan 1f was incubated with the CPO/GOx enzyme mix, with the amount of oxidase relative to the peroxidase (units of GOx vs units of CPO) being systematically reduced (Scheme 4). The comparison between conversion values after 3 h and 24 h indicates how strongly the biocatalytic system is impaired by the different rates of H₂O₂ production. At high peroxide generation rates (GOx/CPO > 1), the peroxidase obviously suffers a rapid deactivation resulting in low consumption of 1f. Since no additional turnover is observed between the first and second measurements, it can be assumed that complete CPO inhibition is taking place within the first three hours. By lowering the oxidase loading, significantly higher conversions up to greater 90% are achieved and the lifetime of the peroxidase is considerably improved. Even at a 100-fold reduction of the GOx, oxidation of the furfuryl alcohol

Scheme 3. Influence of chain length and branching on the CPO-mediated

Achmatowicz rearrangement.

The modified CPO-based Achmatowicz system was subsequently tested on a set of particularly challenging furans that exhibited very low yields under the originally applied conditions (Scheme 5). On a preparative scale, the yields of both the isopropyl- (2f) and the isobutyl-substituted (2g) pyranone were significantly increased by exploiting an aerobic ring expansion protocol that was rate-limited by the reduced GOx loading (GOx/CPO = 0.03). Utilizing enantioenriched 1f (97% ee), the desired pyranone was obtained in optically pure form, clearly indicating that despite the extended reaction times, racemization of the furfuryl alcohols is not an issue. Notably, under identical conditions, also highly problematic substrates such as the tertiary alcohol 1r or the core-substituted 3-methylfurfuryl alcohol 1s were oxidatively converted to the corresponding pyranones 2r and 2s, respectively, achieving moderate to very high yields after a reaction time of 18 h.

FULL PAPER



Scheme 5. Optimization towards slowly reacting furfuryl substrates.

Alternative Systems

While the peroxidase/oxidase system for the biocatalytic ring expansion of furanols proved to be effective for a wide range of substrates with little to no bias towards existing stereogenic elements, the structural limitation regarding chain length and furan core substitution prompted us to reconsider alternative systems that would be independent on a productive active site binding of the furans. Here, the original protocol by Lefebvre utilizing peracids as oxidant for the rearrangement ^[5] reaction served as the template for an enzyme cascade design providing a pathway for the catalytic generation of peracetic acid as diffusible redox mediator. Replacement of the peroxidase biocatalyst by a lipase (from Candida antarctica type B) rendered a system where glucose oxidase provided hydrogen peroxide to be used by the lipase to catalyze the perhydrolysis of acetic acid (from an acidic acetate buffer, pH 4.5).[11] To our delight, 1-(5methylfuryl)ethanol (1n), previously not affected by the peroxidase/oxidase treatment, was converted smoothly under these modified conditions and gave rise to the desired 2,6dimethylpyranone 2n in moderate yield (Scheme 6).



Scheme 6. Aerobic ring expansion of the core-substituted furan 1x by a oxidase/lipase couple.

Considering the relatively long reaction times and an unfavorable pH profile of the aqueous perhydrolysis approach with regard to furanol racemization issues, we envisaged that the unique ability of lipases to perform in non-aqueous reaction media might be of benefit in the further optimization process. Moving away from an aerobic protocol based on the oxidase-mediated activation of aerial oxygen, the robustness of the hydrolase enzyme towards both high H₂O₂ concentrations and organic solvents was expected to give rise to a simplified system. Consequently, immobilized C. antarctica lipase B was used in ethyl acetate providing good solubility for all tested furfuryl alcohols. Upon addition of aqueous hydrogen peroxide, the perhydrolysis activity of the lipase delivered the required peracid and smooth conversion to the desired pyranones was observed (Scheme 7a). Moderate to mainly good yields were achieved for a series of furan substrates that proved to be inert to the chloroperoxidase methodology.^[24] In addition, the use of a peracetic acid mediator system also allowed for a productive aza-Achmatowicz rearrangement of the furyl carbamate 3 giving rise to piperidinone 4 in 65% yield (Scheme 7b).

a oxa-Achmatowicz



Scheme 7. Lipase-mediated oxa- and aza-Achmatowicz-type ring expansions.

phosphate buffer (pH 7.0), r.t.

4,65%

Conclusions

3

In summary, the commercial chloroperoxidase from *Caldariomyces fumago* exhibits high activity and a broad substrate scope in the oxidative ring expansion of furfuryl alcohols. Thanks to the absence of significant enantiodiscrimination of the

heme protein, optically active substrates can be converted to the corresponding enantioenriched pyranones with high effectivity independent on their sense of chirality. An H_2O_2 generation system based on glucose and glucose oxidase allows for an accurate fine tuning of the aerobic protocol in order to adapt to the efficacy of the heme enzyme on different furan derivatives providing full conversions and high yields even for very slowly reacting substrates.

Experimental Section

Commercially available reagents were used without further purification. Furfuryl alcohols and furyl carbamates were synthesized as previously described.^[11,24] Catalysts and cofactors were obtained from: NADH, Carbolution Chemicals GmbH; lactoperoxidase from Bos taurus (LPO, 106 U/mg, Bio-Research Products Inc.), peroxidase from Armoracia rusticana (HRP, 148 U/mg, Sigma); peroxidase from Glycine max (SBP, 17.5 kU/mL, **Bio-Research** Products Inc.); chloroperoxidase from Caldariomyces fumago (CPO, 10.0 kU/mL, Sigma), glucose oxidase type II from Aspergillus niger (GOx, 19.3 U/mg, Sigma); L-Amino acid oxidase from Crotalus atrox (0.1 U/mg, Sigma); alcohol dehydrogenase recombinant from Escherichia coli (ADH 200, 17.6 U/mg evocatal GmbH); alcohol dehydrogenase, recombinant from Escherichia coli (ADH 030, 18.8 U/mg, evocatal GmbH); glucose dehydrogenase, recombinant from Escherichia coli (GDH 060, 214 U/mg, evocatal GmbH); Lipase from Candida sp., recombinant from Aspergillus niger, non-immobilized (7.3 kU/mL, Sigma); immobilized recombinant Lipase B from Candida antarctica, (14.3 kU/g, c-LEcta GmbH); catalase from Corynebacterium glutamicum (500 kU/mL, Sigma). Enzymatic reactions were performed under non-inert conditions on an orbital shaker in open glass vials or round bottom flasks. Column chromatography was performed with silica gel from Merck (Millipore 60, 40-60 µm, 240-400 mesh). Reactions were monitored by thin layer chromatography (TLC) carried out on Macherey-Nagel pre-coated silica gel plates (TLC Silica gel 60 F254). Visualisation of the TLC plates was done by using UV light or staining with a basic potassium permanganate solution. ¹H and ¹³C NMR spectra were recorded on Bruker instruments (Avance 300 or Avance 400) at 20 °C. Chemical shifts are reported in parts per million (ppm) calibrated using residual non-deuterated solvent as internal reference (CHCl₃ at δ = 7.26 ppm (¹H NMR) and δ = 77.16 ppm (¹³C NMR)). Infrared spectra were recorded on a Bruker ALPHA Eco-ATR spectrometer, absorption bands are reported in wave numbers [cm⁻¹]. High resolution mass spectrometry was performed on an Agilent 6530 (Q-TOF) mass spectrometer. Optical rotations were measured on an Autopol VI polarimeter from Rudolph Research Analytical. Uncorrected melting points were measured on a Stuart SMP30 melting point apparatus using open glass capillaries. Gas chromatography analysis was performed on a Hewlett Packard HP 6890 Series GC System using a Macherey-Nagel FS-Lipodex E column (25 m x 0.25 mm), N₂, 1.0 ml/min: 50 °C (1 min) / 5 °C·min⁻¹ (35 min) / 120 °C (15 min).

General procedure for the chloroperoxidase-mediated oxidative ring expansion: In a 100 mL round bottom flask, the furylcarbinol (10 mM, 0.5 mmol) was dissolved in a mixture of citrate buffer (45 mL, 100 mM, pH 5.5) and *tert*-butanol (5 mL). After addition of chloroperoxidase (500 U), glucose oxidase (500 U) and D-glucose (50 mM), the solution was incubated at 30 °C (200 rpm) for 120 -180 min. L-Methionine (250 mg) was added and the reaction mixture was extracted with ethyl acetate (3 x 15 mL). The combined organic layers were dried over MgSO₄, evaporated under reduced pressure and the pyranone was obtained after column chromatographic purification (SiO₂, hexanes/ethyl acetate) as mixture of inseparable diastereomers.

6-Hydroxy-2-methyl-2H-pyran-3(6H)-one (2a): Colorless solid (53.4 mg, 0.417 mmol, 83% yield; $\alpha/\beta = 67/33$). $[\alpha]^{20}_{D}$: -79.6 (c 0.50, CHCl₃), 99% ee, if starting from (R)-1a. M.p.: 61 °C. R_f (cyclohexane/ethyl acetate, 2/1): 0.25. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.89 (dd, ³J = 10.2 Hz, ³J = 3.2 Hz, 1H), 6.10 (d, ${}^{3}J$ = 10.2 Hz, 1H), 5.63 (m, 1H), 4.71 (q, ${}^{3}J$ = 6.7 Hz, 1H), 3.53 (d, ³*J* = 5.0 Hz, 1H), 1.38 (d, ³*J* = 6.7 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 197.0, 144.5, 127.3, 87.7, 70.4, 15.3. Minor isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.94 (d, ³J = 10.2 Hz, 1H), 6.15 (d, ${}^{3}J$ = 10.2 Hz, 1H), 5.67 (d, ${}^{3}J$ = 7.2 Hz, 1H), 4.23 (1H, m), 3.87 (d, ³*J* = 7.2 Hz, 1H), 1.45 (d, ³*J* = 6.7 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 196.5, 148.1, 128.6, 91.0, 75.3, 16.2. FT-IR (neat, ATR): v [cm⁻¹] = 3294 (br), 3051 (w), 2987 (w), 1676 (s), 1435 (m), 1371 (m), 1334 (w), 1273 (w), 1232 (m), 1143 (m), 1109 (m), 1091 (m), 1031 (s), 937 (m), 900 (m), 808 (m), 690 (m). GC: α -(2*R*)-2a = 37.0 min, α -(2*S*)-2a = 37.6 min. This reaction was also successfully scaled up to a preparative level: 1a (5.61 g, 50 mmol), D-glucose (10.8 g, 60 mmol), glucose oxidase (5 kU), chloroperoxidase (10 kU) in citrate buffer (900 mL, 100 mM, pH 5.5) and tert-butanol (100 mL), 30 °C, 5 h, to yield 2a (4.91 g (38.2 mmol) after chromatographic purification.

6-Hydroxy-2-ethyl-2*H***-pyran-3(6***H***)-one (2b): Colorless oil (54.9 mg, 386 μmol, 77% yield; \alpha/\beta = 68/32). [\alpha]²⁰_D: -24.9 (c 0.55, CHCl₃), 99% ee, if starting from (***R***)-1b. R_f (cyclohexane/ethyl acetate, 2/1): 0.27. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.97-6.89 (dd, ³***J* **= 10.4 Hz, ³***J* **= 3.4 Hz, 1H), 6.18-6.10 (d, ³***J* **= 10.3 Hz, 1H), 5.68 (m, 1H), 4.53 (dd, ³***J* **= 7.4 Hz, ³***J* **= 4.1 Hz, 1H), 3.37 (s, 1H), 2.06-1.71 (m, 2H), 1.06-0.97 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 196.2, 144.4, 127.7, 87.7, 75.2, 23.0, 23.0, 9.32. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 4.06-4.02 (m, 1H), 3.65 (dd, ³***J* **= 7.3 Hz, ³***J* **= 4.1 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 147.8, 128.8, 90.9, 80.0, 23.9, 9.6. FT-IR (neat, ATR): v [cm⁻¹] = 3307 (br), 2978 (w), 1666 (s), 1458 (w), 1377 (m), 1267 (m), 1234 (m), 1161 (m), 1112 (m), 1080 (m), 1026 (s), 960 (m), 889 (w), 777 (m), 750 (m), 692 (m).**

6-Hydroxy-2-propyl-2*H***-pyran-3(6***H***)-one (2c):** Colorless oil (41.4 mg, 265 μmol, 53% yield; $\alpha/\beta = 65/35$). [α]²⁰_D: -17.9 (c 0.52, CHCl₃), 98% ee, if starting from (*R*)-1c. R_f (cyclohexane/ethyl acetate, 2/1): 0.29. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.92 (dd, ³*J* = 10.1 Hz, ³*J* = 3.2 Hz, 1H), 6.15 (d, ³*J* = 10.2 Hz, 1H), 5.68-5.64 (m, 1H), 4.58 (dd, ³*J* = 8.1 Hz, ³*J* = 3.9 Hz, 1H), 3.17 (br s, 1H), 2.10-1.39 (m, 4H), 0.96 (t, ³*J* = 7.4 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 194.8, 144.3, 127.6, 87.6, 74.0, 31.6, 18.2, 13.8. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 4.10 (dd, ³*J* = 8.2 Hz, ³*J* = 4.1 Hz, 1H), 0.92 (t, ³*J* = 7.4 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 417.7, 128.8, 91.1, 78.7, 32.6, 18.2, 13.8. FT-IR (neat, ATR): v [cm⁻¹] = 3394 (br), 2960 (m), 2873 (w), 1685 (s), 1458 (m), 1375 (m), 1265 (m), 1215 (w), 1157 (w), 1083 (m), 1020 (s), 914 (w), 759 (w). GC: α-(2*R*)-2c = 41.0 min, α-(2*S*)-2c = 41.9 min.

6-Hydroxy-2-allyl-2H-pyran-3(6H)-one (2e): Colorless oil (50.1 mg, 325 μ mol, 65% yield; α/β = 69/31). [α]²⁰_D: -33.6 (c 0.59, CHCl₃), 98% ee, if starting from (R)-1e. R_f (cyclohexane/ethyl acetate, 2/1): 0.27. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ $[ppm] = 6.90 (dd, {}^{3}J = 10.3 Hz, {}^{3}J = 3.7 Hz, 1H), 6.11 (d, {}^{3}J = 10.3 Hz, 1H)$ Hz, 1H), 5.89-5.78 (m, 1H), 5.66 (m, 1H), 5.18-5.09 (m, 2H), 4.67 (dd, ${}^{3}J$ = 8.0 Hz, ${}^{3}J$ = 3.8 Hz, 1H), 2.73-2.71 (m, 1H), 2.58-2.46 (m, 1H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 195.9, 144.5, 133.7, 127.6, 118.1, 87.7, 73.7, 34.1. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.94 (dd, ³J = 10.2 Hz, ³J = 1.6 Hz, 1H), 6.16 (d, ${}^{3}J$ = 10.2 Hz, 1H), 4.18-4.16 (dd, ${}^{3}J$ = 8.2 Hz, ${}^{3}J$ = 3.9 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃): δ = 195.8, 147.9, 133.6, 128.6, 117.8, 90.8, 78.5, 35.1. FT-IR (neat, ATR): v [cm⁻¹] = 3381 (br), 2958 (w), 1685 (s), 1431 (w), 1373 (w), 1267 (w), 1211 (w), 1155 (w), 1087 (m), 1022 (s), 918 (m), 800 (w), 765 (w). GC: α-(2R)-**2e** = 41.9 min, α -(2S)-**2e** = 43.1 min.

6-Hydroxy-2-*tert***-butyl-2***H***-pyran-3(6***H***)-one (2h): Colorless oil (6.8 mg, 40 μmol, 4% yield; α/β = 70/30). R_f (cyclohexane/ethyl acetate, 2/1): 0.35. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.84 (dd, ³***J* **= 10.2 Hz, ³***J* **= 3.2 Hz, 1H), 6.04 (d, ³***J* **= 10.2 Hz, 1H), 5.66 (d, ³***J* **= 3.2 Hz, 1H), 4.21 (s, 1H), 3.48 (br s, 1H), 1.06 (s, 9H); ¹³C-NMR (75 MHz, CDCl₃): δ [ppm] = 196.8, 143.4, 128.8, 87.9, 80.2, 34.9, 26.3. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.89-6.85 (m, 1H), 6.10- 6.06 (m, 1H), 5.60 (m, 1H), 3.70 (s, 1H), 3.69 (d, ³***J* **= 1.2 Hz, 1H), 1.09 (s, 9H); ¹³C-NMR (75 MHz, CDCl₃): δ [ppm] = 196.1, 147.1, 130.4, 91.8, 85.1. FT-IR (neat, ATR): v [cm⁻¹] = 3371 (br), 2958 (m), 2872 (w), 1726 (m), 1681 (s), 1633 (w), 1463 (w), 1363 (m), 1300 (m), 1234 (m), 1182 (m), 1089 (m), 1026 (s), 1004 (s), 968 (m), 900 (m), 821 (w), 746 (m).**

6-Hydroxy-2-phenyl-2*H***-pyran-3(6***H***)-one (2i):** Colorless oil (25.2 mg, 132 μmol, 26% yield; α/β = 75/25). R_f (cyclohexane/ethyl acetate, 2/1): 0.30. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 7.41-7.33 (m, 5H), 6.95 (dd, ³*J* = 10.2 Hz, ³*J* = 3.3 Hz, 1H), 6.21 (d, ³*J* = 10.3 Hz, 1H), 5.73-5.71

(m, 1H), 5.59 (s, 1H), 3.44 (d, ${}^{3}J$ = 5.1 Hz, 1H); ${}^{13}C$ NMR (75 MHz, CDCl₃): δ [ppm] = 194.5, 144.8, 135.2, 128.6, 128.5, 128.0, 127.9, 88.0, 77.0. Minor isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 7.41-7.33 (m, 5H), 7.01-6.97 (m, 1H), 6.26 (dd, ${}^{3}J$ = 10.3 Hz, ${}^{4}J$ = 1.6 Hz, 1H), 5.79-5.76 (m, 1H), 5.09 (d, ${}^{3}J$ = 1.5 Hz, 1H), 3.64 (d, ${}^{3}J$ = 7.2 Hz, 1H); ${}^{13}C$ NMR (75 MHz, CDCl₃): δ [ppm] = 194.1, 148.2, 128.3, 91.5, 81.1. FT-IR (neat, ATR): v [cm⁻¹] = 3392 (br), 1689 (s), 1629 (w), 1469 (w), 1454 (m), 1371 (w), 1290 (m), 1219 (m), 1089 (m), 1074 (m), 1024 (s), 1002 (s), 945 (m), 891 (m), 794 (w), 750 (s), 698 (s).

6-Hydroxy-2-ethoxycarbonylmethyl-2H-pyran-3(6H)-one (2j): Colorless oil (68.1 mg, 340 µmol, 68% yield; $\alpha/\beta = 72/28$). $[\alpha]^{20}$ D: +7.4 (c 1.00, CHCl₃), 99% ee, if starting from (R)-1j. R_f (cyclohexane/ethyl acetate, 2/1): 0.19. Major isomer: ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3)$: δ [ppm] = 6.93 (dd, ${}^{3}J$ = 10.3 Hz, ${}^{3}J$ = 3.5 Hz, 1H), 6.17 (d, ${}^{3}J$ = 10.3 Hz, 1H), 5.75-5.53 (m, 1H), 5.03 (dd, ${}^{3}J$ = 7.2 Hz, ${}^{3}J$ = 4.0 Hz, 1H), 3.00-2.98 (m, 1H), 2.85-2.68 (m, 1H), 1.30-1.25 (m, 3H). ¹³C NMR (75 MHz, CDCl₃): δ [ppm] =195.0, 171.0, 144.6, 127.1, 87.4, 70.7, 61.0, 35.3, 14.1. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.98 (dd, ${}^{3}J$ = 10.3 Hz, ${}^{3}J$ = 1.5 Hz, 1H), 6.13 (dd, ${}^{3}J$ = 10.3 Hz, ${}^{3}J$ = 1.5 Hz, 1H), 4.61-4.57 (m, 1H), 4.21-4.13 (m, 3H), 3.06-3.03 (m, 1H). ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 194.4, 171.0, 148.4, 128.4, 90.9, 75.3, 67.4, 36.2, 14.1. FT-IR (neat, ATR): $v [cm^{-1}] = 3420$ (br), 2988 (w), 1732 (m), 1693 (m), 1375 (w), 1286 (w), 1178 (m), 1089 (m9 1020 (s), 931 (w), 846 (w), 759 (w).

6-Hydroxy-2-chloromethyl-2*H*-pyran-3(6*H*)-one (2k):

Colorless solid (52.0 mg, 320 µmol, 64% yield; $\alpha/\beta = 64/36$). [α]²⁰_D: -2.8 (c 0.51, CHCl₃), 99% *ee*, if starting from (S)-**1k**. M.p.: 75 °C. R_f (cyclohexane/ethyl acetate, 2/1): 0.23. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 7.00 (dd, ³*J* = 10.3 Hz, ³*J* = 3.6 Hz, 1H), 6.19 (d, ³*J* = 10.3 Hz, 1H), 5.79 (m, 1H), 4.90 (dd, ³*J* = 5.5 Hz, ³*J* = 3.2 Hz, 1H), 3.98-3.92 (m, 2H), 3.62-3.58 (m, 1H). ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 193.0, 145.1, 127.5, 87.9, 74.0, 42.9. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ ppm] = 7.03 (dd, ³*J* = 10.3 Hz, ³*J* = 1.6 Hz, 1H), 6.23 (dd, ³*J* = 1.5 Hz, ³*J* = 10.3 Hz, 1H), 4.43 (dd, ³*J* = 6.3 Hz, ³*J* = 3.8 Hz, 1H), 4.01-3.99 (m, 1H). ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 192.6, 148.2, 128.4, 90.4, 78.5, 43.7. FT-IR (neat, ATR): v [cm⁻¹] = 3329 (br), 1666 (s), 1631 (w), 1436 (w), 1371 (w), 1273 (m), 1232 (m), 1192 (w), 1153 (w), 1107 (m), 1080 (m), 1028 (s), 902 (m), 802 (m), 763(m), 731 (m), 690 (m).

6-Hydroxy-2-hydroxymethyl-2*H***-pyran-3(6***H***)-one (2I):** Yellow oil (22.3 mg, 155 μmol, 31% yield; $\alpha/\beta = 55/44$). [α]²⁰_D: +22.5 (c 0.55, CHCl₃), 99% ee, if starting from (*R*)-**1I**. R_f (cyclohexane/ethyl acetate, 1/1): 0.15. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.98-6.93 (m, 1H), 6.15 (d, ³*J* = 10.3 Hz, 1H), 5.72 (d, ³*J* = 3.4 Hz, 1H), 4.67 (t, ³*J* = 4.5 Hz, 1H), 4.10-3.88 (m, 2H); ¹³C NMR (75 MHz, CDCl₃): δ = 145.0, 127.8, 87.5, 74.1, 61.8. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] =

6.22 (d, ${}^{3}J$ = 10.4 Hz, 1H), 5.65 (d, ${}^{3}J$ = 1.8 Hz, 1H), 4.53 (t, ${}^{3}J$ = 3.5 Hz, 1H); ${}^{13}C$ NMR (75 MHz, CDCl₃): δ =146.9, 128.5. FT-IR (neat, ATR): v [cm⁻¹] = 3392 (br), 2942 (m), 2854 (w), 2358 (s), 2331 (m), 1683 (m), 1465 (m), 1375 (w) 1103 (w), 1029 (m), 769 (w), 669 (m).

6-Hydroxy-2-butyl-2H-pyran-3(6H)-one (2o): Colorless oil (31.5 mg, 185 μ mol, 37% yield; α/β = 76/24). R_f (cyclohexane/ethyl acetate, 2/1): 0.33. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ $[ppm] = 6.80 (dd, {}^{3}J = 10.1 Hz, {}^{3}J = 3.3 Hz, 1H), 6.11 (d, {}^{3}J = 10.4$ Hz, 1H), 5.66 (d, ³J = 3.1 Hz, 1H), 4.56 (q, 3J5,6 = 4.1 Hz, 1H, H-5), 3.00 (br s, 1H, OH), 1.98-1.64 (m, 2H, H-6), 1.48-1.30 (m, 4H, H-7, H-8), 0.91 (t, ${}^{3}J$ = 7.1 Hz, 3H, H-9); ${}^{13}C$ NMR (75 MHz, CDCl₃): δ [ppm] = 196.8 (C-4), 144.1 (C-3), 127.7 (C-2), 87.7 (C-1), 74.2 (C-5), 29.1 (C-6), 26.9, 22.2 (C-7, C-8), 13.9 (C-9). Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.94-6.90 (m, 1H), 6.16- 6.12 (m, 1H), 5.66 (d, ${}^{3}J$ = 3.1 Hz, 1H), 4.09-4.05 (m, 1H), 3.24 (br s, 1H), 1.98-1.64 (m, 2H), 1.48-1.30 (m, 4H), 0.91 (t, ${}^{3}J$ = 7.1 Hz, 3H); ${}^{13}C$ NMR (75 MHz, CDCl₃): δ [ppm] = 147.5, 128.8, 90.9, 79.0, 30.4. FT-IR (neat, ATR): v [cm⁻¹]= 3327 (br), 2949 (m), 2927 (w), 1672 (s), 1627 (w), 1467 (m), 1373 (m), 1309 (w), 1257 (m), 1157 (m), 1187 (w), 1087 (s), 1026 (s), 974 (m), 933 (w), 875 (m), 759 (m).

6-Hydroxy-2-pentyl-2H-pyran-3(6H)-one (2p): Colorless oil (5.7 mg, 31 μ mol, 6% yield; α/β = 74/26). R_f (cyclohexane/ethyl acetate, 2/1): 0.34. Major isomer: ¹H NMR (300 MHz, CDCl₃): δ $[ppm] = 6.88 (dd, {}^{3}J = 10.2 Hz, {}^{3}J = 3.3 Hz, 1H), 6.10 (d, {}^{3}J = 10.3 Hz, 1H)$ Hz, 1H), 5.65 (d, ${}^{3}J$ = 3.0 Hz, 1H), 4.55 (q, ${}^{3}J$ = 3.9 Hz, 1H), 3.03 (br s, 1H), 1.95-1.63 (m, 2H), 1.33-1.20 (m, 6H), 0.90-0.85 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 196.8, 144.1, 127.7, 87.7, 74.3, 31.7, 29.6, 24.9, 22.6, 14.0. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.94-6.90 (m, 1H), 6.16- 6.12 (m, 1H), 5.65 (d, ${}^{3}J$ = 3.0 Hz, 1H), 4.09-4.05 (m, 1H), 3.26 (br s, 1H), 1.95-1.63 (m, 2H), 1.33-1.20 (m, 6H), 0.90-0.85 (m, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 147.5, 128.8, 90.9, 79.2, 30.7, 29.1, 25.1, 22.8. FT-IR (neat, ATR): v [cm⁻¹] = 3317 (br), 2949 (m), 2873 (m), 1674 (s), 1627 (w), 1469 (m), 1375 (m), 1274 (m), 1242 (m), 1157 (m), 1093 (s), 1026 (s), 999 (m), 952 (m), 891 (m), 785 (m), 700 (m).

General procedure for the oxidase-limited modification of the biocatalytic Achmatowicz reaction: The furylcarbinol (0.2 mmol) was dissolved in *tert*-Butanol (2 mL) and the solution was added to a mixture of chloroperoxidase (200 U), glucose oxidase (6 U) in citrate buffer (18 mL, 100 mM, pH 6.0). After addition of D-glucose (50 mM), the reaction mixture was incubated at 30 °C (200 rpm) overnight. L-Methionine (250 mg) was added and the reaction mixture was extracted with ethyl acetate (3 x 5 mL). The combined organic layers were dried over MgSO₄, evaporated under reduced pressure and the pyranone was obtained after purification by column chromatography (SiO₂, hexanes/ethyl acetate). 6-Hydroxy-2-isopropyl-2H-pyran-3(6H)-one (2f): Colorless oil (26.9 mg, 172 μ mol, 86% yield; α/β = 73/27). [α]²⁰_D: -8.6 (c 0.50, CHCl₃), 99% ee, if starting from (R)-1f. R_f (cyclohexane/ethyl acetate, 2/1): 0.32. Major isomer: ¹H-NMR (300 MHz, CDCl₃): δ $[ppm] = 6.93 (dd, {}^{3}J = 10.2 Hz, {}^{3}J = 3.4 Hz, 1H), 6.12 (d, {}^{3}J = 10.2 Hz, {}^{3}J = 10.2 Hz, 1H)$ Hz, 1H), 5.71-5.65 (m, 1H), 4.43 (d, ${}^{3}J$ = 3.4 Hz, 1H), 3.15-3.10 (m, 1H), 2.52-2.41 (m, 1H), 1.05 (d, ³J = 7.1 Hz, 3H), 0.90 (d, ³J = 6.9 Hz, 3H); ¹³C-NMR (75 MHz, CDCl₃): δ [ppm] = 196.2, 144.2, 128.1, 87.7, 77.3, 28.6, 19.0, 16.2. Minor isomer (selected signals): ¹H NMR (300 MHz, CDCl₃): δ [ppm] = 6.14 (dd, ³J = 10.3 Hz, ${}^{3}J$ = 1.5 Hz, 1H), 3.93 (dd, ${}^{3}J$ = 3.4 Hz, ${}^{3}J$ = 1.3 Hz, 1H), 3.43-3.37 (m, 1H), 0.96 (d, ³*J* = 6.8 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ [ppm] = 148.0, 129.5, 91.2, 83.1, 28.9, 19.1, 16.5. FT-IR (neat, ATR): $v [cm^{-1}] = 3385$ (br), 2966 (w), 1681 (m), 1463 (w), 1369 (m), 1273 (w), 1230 (w), 1153 (w), 1082 (m), 1016 (s), 946 (m), 885 (w), 756 (m), 680 (w). GC: α -(2R)-2f = 38.7 min, α -(2S)-2f = 39.9 min.

6-Hydroxy-2-isobutyl-2H-pyran-3(6H)-one (2g): Colorless oil (30.3 mg, 178 µmol, 89% yield; α/β = 70/30). R_f (cyclohexane/ethyl acetate, 2/1): 0.48. Major isomer: ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.90 (dd, ³J = 10.2 Hz, ³J = 3.4 Hz, 1 H), 6.12 (d, ${}^{3}J$ = 10.2 Hz, 1 H), 5.66 (d, ${}^{3}J$ = 3.4 Hz, 1 H), 4.63 $(dd, {}^{3}J = 9.7 Hz, {}^{3}J = 3.3 Hz, 1 H), 1.77-1.91 (m, 2 H), 1.57-1.75$ (m, 1 H), 0.92-1.02 (m, 6 H); ¹³C NMR (100 MHz, CDCl₃): δ [ppm] = 193.1, 143.9, 127.8, 87.4, 72.5, 38.2, 24.2, 23.4, 21.2. Minor isomer (selected signals): ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.94 (dd, ${}^{3}J$ = 10.3 Hz, ${}^{3}J$ = 1.6 Hz, 1 H), 6.17 (dd, ${}^{3}J$ = 10.3 Hz, ${}^{4}J = 1.6$ Hz, 1 H), 5.67 (d, ${}^{3}J = 1.6$ Hz, 1 H), 4.15 (dddd, ${}^{3}J = 9.6$ Hz, ${}^{3}J = 3.3$ Hz, ${}^{4}J = 1.2$ Hz, ${}^{4}J = 0.4$ Hz, 1 H); ${}^{13}C$ NMR (100 MHz, CDCl₃): δ [ppm] = 147.1, 129.0, 90.9, 82.3, 39.3. FT-IR (ATR): v [cm⁻¹] = 3307 (br), 2954 (m), 1672 (m), 1629 (w), 1371 (m), 1276 (m), 1157 (m), 1091 (s), 1020 (s), 975 (m), 898 (m), 702 (m). HRMS (ESI): *m*/*z* [M–OH]⁺ calcd for C₉H₁₃O₂: 153.0916; found: 153.0910.

6-Hydroxy-2,2-dimethyl-2*H***-pyran-3(6***H***)-one (2r): Colorless liquid (15.4 mg, 108 μmol, 54 % yield). R_f (cyclohexane/ethyl acetate, 2/1): 0.33. ¹H NMR (CDCl₃, 400 MHz): δ [ppm] = 6.87 (dd, ³***J* **= 10.3 Hz, ³***J* **= 2.2 Hz, 1 H), 6.07 (dd, ³***J* **= 10.3 Hz, ⁴***J* **= 1.3 Hz, 1 H), 5.70-5.68 (m, 1 H), 3.38 (br s, 1 H), 1.49 (s, 3 H), 1.39 (s, 3 H); ¹³C NMR (CDCl₃, 100 MHz): δ [ppm] = 198.9, 145.7, 126.6, 88.0, 79.5, 26.6, 23.9. FT-IR (neat, ATR): v [cm⁻¹] = 3402 (br), 2982 (w), 1681 (s), 1380 (m), 1293 (m), 1238 (m), 1084 (m), 1036 (s), 924 (m).**

6-Hydroxy-4-methyl-2H-pyran-3(6H)-one (2s): Colorless solid (12.3 mg, 96 μmol, 48 % yield). M.p.: 59 °C. R_f (cyclohexane/ethyl acetate, 2/1): 0.25. ¹H NMR (400 MHz. CDCl₃): δ [ppm] = 6.68 (dq, ${}^{3}J$ = 3.1 Hz, ${}^{4}J$ = 1.4 Hz, 1 H), 5.55-5.68 (m, 1 H), 4.56 (d, ${}^{2}J$ = 16.9 Hz, 1 H), 4.12 (d, ${}^{2}J$ = 16.9 Hz, 1 H), 3.32 (br s, 1 H), 1.84 (t, ${}^{4}J$ = 1.4 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ [ppm] = 195.3, 140.8, 135.4, 89.2,

66.6, 14.5. FT-IR (ATR): v [cm⁻¹] = 3409 (br), 2963 (w), 1665 (s), 1434 (m), 1360 (m), 1236 (m), 1144 (m), 1102 (m), 990 (s), 859 (m), 788 (m), 656 (m).

General procedure for the lipase-catalyzed biocatalytic Achmatowicz reaction: The furylcarbinol (5.0 mmol) was dissolved in ethyl acetate (50 mL), and immobilized lipase B from *C. antarctica* (105 mg, 1.5 kU) and aqueous H_2O_2 (50 % v/v, 858 µL, 1.02 g, 15.0 mmol) were added. The reaction mixture was placed on an orbital shaker at 40 °C (200 rpm). After 24 h, phosphate buffer (15 mL, 100 mM, pH 7.0) and catalase (5 µL) were added and the mixture was shaken for additional 15 min. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (10 mL). The combined organic layers were dried over Na_2SO_4 and the volatiles were evaporated under reduced pressure. The pyranone was obtained after purification by column chromatography (SiO₂, hexanes/ethyl acetate).

6-Hydroxy-2,6-dimethyl-2H-pyran-3(6H)-one (2n): Yellow oil (528 mg, 3.71 mmol, 74 % yield; $\alpha/\beta = 84:16$). R_f (cyclohexane/ethyl acetate, 2/1): 0.36. Major isomer: ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.80 (d, ³J = 10.1 Hz, 1 H), 5.99 (d, ${}^{3}J$ = 10.1 Hz, 1 H), 4.63 (q, ${}^{3}J$ = 6.7 Hz, 1 H), 1.61 (s, 3 H), 1.34 (d, ³*J* = 6.7 Hz, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ [ppm] = 197.2, 147.9, 126.1, 92.9, 70.7, 28.9, 15.3. Minor isomer (selected signals): ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.86 (d, ³*J* = 10.2 Hz, 1 H), 4.30 (q, ³*J* = 6.8 Hz, 1 H), 1.59 (s, 3 H), 1.43 (d, ${}^{3}J$ = 6.8 Hz, 3 H); ${}^{13}C$ NMR (100 MHz, CDCl₃): δ [ppm] = 150.1, 126.0, 74.3, 24.3, 17.3. FT-IR (neat, ATR): v [cm⁻¹] = 3302 (m), 2987 (w), 1676 (s), 1444 (m), 1371 (m), 1242 (m), 1145 (m), 1109 (m), 1070 (m), 1028 (s), 939 (m), 688 (m).

6-Hydroxy-2-hexyl-2H-pyran-3(6H)-one (2q): Colorless solid (744 mg, 3.75 mmol, 75 %; α/β = 75:25.). M.p.: 70 °C. R_f (cyclohexane/ethyl acetate, 2/1): 0.45. Major isomer: ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.88 (dd, ³J = 10.2 Hz, ³J = 3.3 Hz, 1 H), 6.10 (d, ${}^{3}J$ = 10.2 Hz, 1 H), 5.65 (d, ${}^{3}J$ = 3.3 Hz, 1 H), 4.55 (dd, ${}^{3}J$ = 8.1 Hz, ${}^{3}J$ = 3.9 Hz, 1 H), 3.08 (br s, 1 H), 1.88-1.96 (m, 1 H), 1.65-1.80 (m, 1 H), 1.24-1.48 (m, 8 H), 0.82-0.92 (m, 3 H); ¹³C NMR (100 MHz, CDCl₃): δ [ppm] = 196.7, 144.3, 127.8, 87.8, 74.4, 31.8, 29.7, 29.2, 25.0, 22.7, 14.2. Minor isomer (selected signals): ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.92 (dd, ${}^{3}J$ = 10.2 Hz, ${}^{3}J$ = 1.5 Hz, 1 H), 6.14 (dd, ${}^{3}J$ = 10.2 Hz, ${}^{4}J$ = 1.5 Hz, 1 H), 4.07 (ddd, ${}^{3}J$ = 8.3 Hz, ${}^{3}J$ = 3.9 Hz, ${}^{4}J$ = 1.0 Hz, 1 H), 3.30 (br s, 1 H). ¹³C NMR (100 MHz, CDCl₃): δ [ppm] = 196.4, 147.6, 128.9, 91.0, 79.1, 30.8, 29.1, 25.2. FT-IR (neat, ATR): v [cm⁻¹] = 3309 (br), 2923 (m), 1673 (s), 1469 (m), 1375 (w), 1275(m), 1157 (m), 1024 (s), 889 (m), 784 (m), 702 (m), 658 (m). HRMS (ESI): *m*/*z* [M+Na]⁺ calcd for C₁₁H₁₈O₃Na: 221.1154; found: 211.1162.

6-Hydroxy-2,4-dimethyl-2*H***-pyran-3(6***H***)-one (2t): Colorless solid (398 mg, 2.80 mmol, 56 %; \alpha/\beta = 88:12). R_f (cyclohexane/ethyl acetate, 1/1): 0.54 Major isomer: ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.86-6.89 (m, 1 H), 5.58-5.60 (m,**

1 H), 4.71 (q, ${}^{3}J$ = 6.8 Hz, 1 H), 3.93 (br s, 1H), 1.83 (s, 3H), 1.39 (d, ${}^{3}J$ = 6.8 Hz, 3H). 13 C NMR (100 MHz, CDCl₃): δ [ppm] = 197.6, 139.7, 134.3, 88.1, 70.2, 15.6, 14.7. Minor isomer: ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.67-6.69 (m, 1H), 5.61-5.63 (m, 1H), 4.22-4.13 (m, 1H), 1.82 (s, 3H), 1.44 (d, ${}^{3}J$ = 6.7 Hz, 3 H). 13 C NMR (100 MHz, CDCl₃): δ [ppm] = 197.2, 143.1, 135.7, 91.0, 74.8, 16.4. FT-IR (neat, ATR): v [cm⁻¹] = 3427 (br), 2984 (w), 1651 (s), 1448 (m), 1367 (m), 1305 (w), 1130 (m), 1091 (s), 1024 (s), 995 (s). HRMS (ESI): *m*/*z* [M+Na]⁺ calcd for C₇H₁₀O₃Na: 165.0527; found: 165.0523.

Benzyl 6-ethyl-2-hydroxy-5-oxo-5,6-dihydropyridine-1(2*H*)carboxylate (4): Yellow oil (82 mg, 0.58 mmol, 65 %; $\alpha/\beta = 80:20$). R_f (cyclohexane/ethyl acetate, 3/2): 0.45. Major isomer: ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 7.38 (m, 5 H), 6.91 (dd, ³J = 10.4 Hz, ³J = 3.9 Hz, 1 H), 6.13 (dd, ³J = 10.4 Hz, ⁴J = 1.2 Hz, 1 H), 6.02-6.09 (m, 1 H), 5.21-5.23 (m, 2 H), 4.51 (t, ³J = 7.3 Hz, 1 H), 1.80-1.92 (m, 2 H), 0.95 (t, ³J = 7.3 Hz, 3 H). ¹³C NMR (100 MHz, CDCl₃): δ [ppm] = 195.4, 151.5, 143.9, 135.5, 128.7,128.6, 128.3, 127.1, 72.2, 68.2, 61.6, 28.9, 10.4. Minor isomer (selected signals): ¹H NMR (400 MHz, CDCl₃): δ [ppm] = 6.80 (dd, ³J = 10.5 Hz, ³J = 3.2 Hz, 1 H). FT-IR (neat, ATR): v [cm⁻¹] = 3428 (br), 2969 (w) 1677 (s), 1426 (w), 1380 (m), 1316 (m), 1069 (m), 1028 (m), 980 (m), 907 (m), 809 (w), 726 (s), 695 (s). HRMS (ESI): m/z [M+Na]⁺ calcd for C₁₅H₁₇NO₄: 298.1050; found: 298.1049.

Acknowledgements

Financial support by the by the Suomen Akatemia (298250), the Deutsche Forschungsgemeinschaft (DE1599/4-1), the Fonds der Chemischen Industrie and the Dr.-Otto-Röhm-Gedächtnisstiftung is gratefully acknowledged.

Keywords: biocatalysis • peroxidase • ring expansion • heterocyclic chemistry • furan

- O. Achmatowicz, P. Bukowski, B. Szechner, Z. Zwierzchowska, A. Zamojski, *Tetrahedron* **1971**, *27*, 1973–1996.
- [2] F. van der Pijl, F. L. van Delft, F. J. P. T. Rutjes, *Eur. J. Org. Chem.* 2015, 4811–4829; and references therein.
- [3] A. K. Ghosh, M. Brindisi, *RSC Adv.* 2016, *6*, 111564–111598; and references therein.
- [4] Y. Ma, G. A. O'Doherty, Org. Lett. 2015, 17, 5280–5283.
- [5] R. M. M. Mrozowski, Z. M. Sandusky, R. Vemula, B. Wu, Q. Zhang, D. A. Lannigan, G. A. O'Doherty, *Org. Lett.* **2014**, *16*, 5996–5999.
- [6] O. Achmatowicz, P. Bukowski, Can. J. Chem. 1975, 53, 2524– 2529.
- [7] Y. Lefebvre, Tetrahedron Lett. 1972, 2, 133–136.
- [6] J. Deska, D. Thiel, E. Gianolio, *Synthesis* 2015, 47, 3435–3450; and references therein.
- C. Asta, D. Schmidt, J. Conrad, B. Förster-Frömme, T. Tolasch, U. Beifuss, *RSC Adv.* 2013, *3*, 19259–19263.

- E. Fernández-Fuego, S. H. H. Younes, S. van Rootselaar, R. W.
 M. Aben, R. Renirie, R. Wever, D. Holtmann, F. P. J. T. Rutjes,
 F. Hollmann, ACS Catal. 2016, 6, 5904–5907.
- [11] D. Thiel, D. Doknić, J. Deska, Nat. Commun. 2014, 5, 5278.
- [12] F. Blume, Y.-C. Liu, D. Thiel, J. Deska, J. Mol. Catal. B Enzym. 2016, 134, 280–284.
- [13] Y. Ji, T. Benkovics, G. L. Beutner, C. Sfouggatakis, M. D. Eastgate, D. G. Blackmond, *J. Org. Chem.* **2015**, *80*, 1696– 1702.
- S. C. Khojasteh-Bakht, W. Chen, L. L. Koenigs, R. M. Peter, S. D. Nelson, *Drug Metab. Dispos.* **1999**, 27, 574–580.
- [15] N. Taxak, S. Kaira, P. V. Bharatham, *Inorg. Chem.* 2013, *52*, 13496–13508.
- [16] F. van Rantwijk, R. A. Sheldon, Curr. Opin. Biotech. 2000, 11, 554–564.
- [17] P. R. Ortiz de Montellano, Y. S. Choe, G. DePillis, C. E. Catalano, J. Biol. Chem. 1987, 262, 11641–11646.

- [18] R. Wilson, A. P. F. Turner, *Biosens. Bioelectron.* **1992**, *7*, 165– 185.
- [19] M. Sundaramoorthy, J. Terner, T. L. Poulos, *Structure* **1995**, *15*, 1367–1377.
- [20] C. M. Krest, A. Silakov, J. Rittle, T. H. Yosca, E. L. Onderko, J. C. Calixto, M. T. Green, *Nat. Chem.* 2015, 7, 696–702.
- [21] C.-S. Chen, Y. Fujimoto, G. Girdaukas, C. J. Sih, J. Am. Chem. Soc. 1982, 104, 7294–7299.
- [22] B. Valderrama, M. Ayala, R. Vazquez-Duhalt, Chem. Biol. 2002, 9, 555–565.
- [23] J. R. Cherry, M. H. Lamsa, P. Schneider, J. Vind, A. Svendsen, A. Jones, A. H. Pedersen, *Nat. Biotechnol.* **1999**, *17*, 379–384.
- [24] F. Blume, P. Sprengart, J. Deska, Synlett, 2018, 29, doi: 10.1055/s-0036-1591889.

Entry for the Table of Contents (Please choose one layout)

FULL PAPER



Chloroperoxidase from *Caldariomyces fumago* catalyzes the selective oxidation of a variety of functionalized furfuryl alcohols in an Achmatowicz-type ring expansion. In combination with glucose oxidase as oxygen-activating biocatalyst, a purely enzymatic, aerobic protocol for the synthesis of 6-hydroxypyranone building blocks is obtained.

Biocatalysis

Daniel Thiel, Fabian Blume, Christina Jäger, Jan Deska*

Page No. – Page No.

Chloroperoxidase-catalyzed Achmatowicz Rearrangements